{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:49:08Z","timestamp":1790812148646,"version":"4.1.0"},"reference-count":27,"publisher":"The Society for Free Radical Research Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2017]]},"DOI":"10.3164\/jcbn.16-122","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T22:11:15Z","timestamp":1494886275000},"page":"53-59","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of tolvaptan monotherapy and low-dose furosemide\/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model"],"prefix":"10.3164","volume":"61","author":[{"given":"Norikazu","family":"Tanabe","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"},{"name":"Center of Research and Education for Regenerative Medicine, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"},{"name":"Department of Oncology & Laboratory Medicine, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"},{"name":"Yamaguchi University Health Administration Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Sol\u00e0 E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012; 57: 1199\u20131206.","DOI":"10.1016\/j.jhep.2012.07.020"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17: 163\u2013173.","DOI":"10.1055\/s-2007-1007195"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol 2012; 27: 11\u201320.","DOI":"10.1111\/j.1440-1746.2011.06925.x"},{"key":"4","unstructured":"4 Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis 2011; 4: 57\u201371."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73\u201382.","DOI":"10.1111\/hepr.12098"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Yamazaki T, Izumi Y, Nakamura Y, et al. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail 2012; 5: 794\u2013802.","DOI":"10.1161\/CIRCHEARTFAILURE.112.968750"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Yamazaki T, Nakamura Y, Shiota M, et al. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci 2013; 123: 58\u201366.","DOI":"10.1254\/jphs.13086FP"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1\u20138.","DOI":"10.1042\/CS20030062"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Saeki I, Terai S, Fujisawa K, et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol 2013; 48: 738\u2013750.","DOI":"10.1007\/s00535-012-0675-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Parent R, Marion MJ, Furio L, Tr\u00e9po C, Petit MA. Origin and charac-terization of a human bipotent liver progenitor cell line. Gastroenterology 2004; 126: 1147\u20131156.","DOI":"10.1053\/j.gastro.2004.01.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cerec V, Glaise D, Garnier D, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007; 45: 957\u2013967.","DOI":"10.1002\/hep.21536"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 C\u00e1rdenas A, Arroyo V. Refractory ascites. Dig Dis 2005; 23: 30\u201338.","DOI":"10.1159\/000084723"},{"key":"13","unstructured":"13 Bernardi M, De Palma R, Trevisani F, Santini C, Servadei D, Gasbarrini G. Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis. Z Kardiol 1985; 74 Suppl 2: 129\u2013134."},{"key":"14","unstructured":"14 Gin\u00e9s P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234\u2013241."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Fede G, D&apos;Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810\u2013818.","DOI":"10.1016\/j.jhep.2011.10.016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Iwasa M, Ishihara T, Hasegawa H, Takei Y. Cirrhosis-related hyponatremia and the role of tolvaptan. Hepatol Res 2015; 45: E163\u2013E165.","DOI":"10.1111\/hepr.12471"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol 2015; 50: 1047\u20131053.","DOI":"10.1007\/s00535-015-1052-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ishikawa M, Kobayashi N, Sugiyama F, Onoda S, Ishimitsu T. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int Heart J 2013; 54: 98\u2013106.","DOI":"10.1536\/ihj.54.98"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999; 44: 560\u2013569.","DOI":"10.1023\/A:1026661508553"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Valgimigli L, Valgimigli M, Gaiani S, Pedulli GF, Bolondi L. Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radic Res 2000; 33: 167\u2013178.","DOI":"10.1080\/10715760000300721"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59\u201369.","DOI":"10.1016\/j.freeradbiomed.2011.10.003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288\u2013294.","DOI":"10.1016\/S0022-3565(24)35289-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34 (4 Pt 1): 745\u2013750.","DOI":"10.1053\/jhep.2001.28231"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Lahet JJ, Lenfant F, Courderot-Masuyer C, et al. <i>In vivo<\/i> and <i>in vitro<\/i> antioxidant properties of furosemide. Life Sci 2003; 73: 1075\u20131082.","DOI":"10.1016\/S0024-3205(03)00382-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kang MY, Tsuchiya M, Packer L, Manabe M. <i>In vitro<\/i> study on antioxidant potential of various drugs used in the perioperative period. Acta Anaesthesiol Scand 1998; 42: 4\u201312.","DOI":"10.1111\/j.1399-6576.1998.tb05073.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Wu Y, Beland FA, Chen S, Liu F, Guo L, Fang JL. Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol 2015; 95: 324\u2013336.","DOI":"10.1016\/j.bcp.2015.03.015"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K; ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res 2012; 40: 2381\u20132393.","DOI":"10.1177\/030006051204000637"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/61\/1\/61_16-122\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:28:53Z","timestamp":1750264133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/61\/1\/61_16-122\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.16-122","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}